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BRIEF DEFINITIVE REPORT
        Acute lymphoblastic leukemia (ALL) comprises 
a biologically heterogeneous group of clonal 
disorders that originate from the uncontrolled 
proliferation and expansion of immature lym-
phoblastic cells and are characterized by an ex-
tremely variable clinical outcome (  1, 2  ). In recent 
years, substantial progress has been made toward 
understanding the molecular events contributing 
to malignant transformation. This has permitted 
the recognition of relevant prognostic factors 
and risk stratifi  cation, and has favored the im-
plementation of therapeutic approaches based on 
cytogenetic and molecular lesions (  2  –  5  ). Despite 
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  Aberrant signal transduction contributes substantially to leukemogenesis. The   Janus kinase 1   
(  JAK1  ) gene encodes a cytoplasmic tyrosine kinase that noncovalently associates with a 
variety of cytokine receptors and plays a nonredundant role in lymphoid cell precursor 
proliferation, survival, and differentiation. We report that somatic mutations in   JAK1   occur 
in individuals with acute lymphoblastic leukemia (ALL).   JAK1   mutations were more preva-
lent among adult subjects with the T cell precursor ALL, where they accounted for 18% of 
cases, and were associated with advanced age at diagnosis, poor response to therapy, and 
overall prognosis. All mutations were missense, and some were predicted to destabilize 
interdomain interactions controlling the activity of the kinase. Three mutations that were 
studied promoted JAK1 gain of function and conferred interleukin (IL)-3  –  independent 
growth in Ba/F3 cells and/or IL-9  –  independent resistance to dexamethasone-induced 
apoptosis in T cell lymphoma BW5147 cells. Such effects were associated with variably 
enhanced activation of multiple downstream signaling pathways. Leukemic cells with 
mutated   JAK1   alleles shared a gene expression signature characterized by transcriptional 
up-regulation of genes positively controlled by JAK signaling. Our fi  ndings implicate dys-
regulated JAK1 function in ALL, particularly of T cell origin, and point to this kinase as a 
target for the development of novel antileukemic drugs. 752 SOMATIC   JAK1   MUTATIONS IN ALL | Flex et al.
(  Fig. 1 A   and   Table I  ).   To verify that the nonsynonymous 
substitutions identifi   ed in patients for whom nonleukemic 
DNA was not available were not gene variants occurring in 
the population, 335 population-matching control individuals 
were analyzed, and none harbored the 611A  >  T (Lys204Met), 
2635C  >  A (Arg879Ser), 2635C  >  T (Arg879Cys), and 2636G  >  A 
(Arg879His) changes or other defects altering those codons. 
Although the T-ALL  –  restricted occurrence of three distinct 
substitutions aff  ecting Arg  879   (3/38 versus 0/335; Fisher  ’  s 
exact probability   <   0.001) further supported the relevance 
of the substitution of this residue, we could not exclude that 
the 611A  >  T change might represent a private neutral variant. 
The two remaining missense changes, 184A  >  G (Ile62Val) and 
1078C  >  T (Arg360Trp), were deemed nonpathogenic vari-
ants, as they were observed in nonleukemic cells of aff  ected 
patients or in unaff  ected control subjects. 
  All mutations occurred as heterozygous changes and af-
fected conserved residues within the FERM, SH2, pseudoki-
nase, and kinase domains (  Fig. 1 B  ). In two cases, DHPLC 
profi  les and electropherograms indicated that the mutant al-
lele might be present in only a fraction of leukemic cells, 
suggesting that these lesions did not represent early events 
during leukemogenesis but were acquired during disease pro-
gression (  Fig. 1 C  ). Remarkably, mutations were relatively 
common among individuals with T-ALL (18.4% of cases, 
95% CI = 7.7  –  34.3%), whereas they occurred in only three 
patients with B-ALL (3.4% of cases, 95% CI = 0.7  –  9.6%; 
  Table I  ). Such a diff  erence in mutation prevalence between 
cohorts was statistically signifi  cant (Fisher  ’  s exact probability = 
0.003). DHPLC screening performed on aff  ected exons by 
using pooled DNAs excluded loss of the normal allele and a 
homozygous condition for a gene variant caused by mitotic 
recombination in all cases. 
  To investigate the prevalence of   JAK1   mutations among 
pediatric ALL cases, genomic DNA from BM obtained at di-
agnosis was scanned for mutations in aff  ected exons. No le-
sion was observed within the B-ALL cohort (  n   = 85), whereas 
a nonsynonymous 1957C  >  T transition (Leu653Phe) was 
identifi  ed in 1 of 49 subjects with T-ALL (2.0% of cases, 95% 
CI = 0.05  –  10.9%). This mutation was not observed in the 
BM obtained from the patient at the time of remission, indi-
cating that it was somatically acquired in the leukemic cells. 
  Overall, these results indicated that   JAK1   gene mutations 
occur in ALL and are more frequently observed among adult 
individuals with involvement of the T cell lineage. 
  Functional consequences of somatic   JAK1   mutations 
  To examine the eff  ects of the identifi  ed mutations on protein 
function, WT JAK1 or a mutant form (A634D, R724H, and 
R879C) was expressed transiently in JAK1-defective human 
fi  brosarcoma U4C cells, and endogenous STAT1 phosphory-
lation was compared basally and after stimulation with IFN-     
(  Fig. 2 A  ).   Consistent with previous studies (  10, 11  ), untrans-
fected cells lacking functional JAK1 did not exhibit STAT1 
phosphorylation in response to IFN-    . All JAK1 mutants 
promoted an enhanced response to the ligand compared with 
these accomplishments, long-term survival in adults with ALL 
remains largely unsatisfactory, making the design of novel an-
tileukemic drugs tailored to specifi  c biological targets a current 
priority (  4, 6  ). 
  The four mammalian members of the JAK family (JAK1, 
JAK2, JAK3, and TYK2) are nonreceptor tyrosine kinases 
functioning as signal transducers to control cellular prolifera-
tion, survival, and diff  erentiation (  7, 8  ). JAK proteins associ-
ate constitutively with a variety of cytokine receptors lacking 
intrinsic kinase activity, and promote signal fl  ow by phos-
phorylating tyrosyl residues of activated receptors to allow the 
recruitment and activation of STAT proteins. They share a 
complex multidomain structure characterized by a tyrosine 
kinase domain at the C terminus, which is fl  anked by a catalyti-
cally inactive pseudokinase domain with regulatory function. 
Their N-terminal half contains a FERM homology domain, 
which is implicated in receptor binding and possibly regulates 
the catalytic activity of the kinase, and an adjacent SH2-like 
domain. In contrast to their conserved structure, increasing 
experimental data indicate that JAK family members prefer-
entially associate with a diverse subset of cytokine receptors, 
each diff  erentially expressed by individual cell lineages and 
tissues, facilitating specifi  city in function (  9  ). Among them, 
JAK1 plays an essential and nonredundant role in mediat-
ing biological responses induced by a specifi  c subgroup of 
cytokines controlling lymphoid cell precursor development 
(  10  ).   Jak1        /      mouse pups exhibit a thymus that is markedly 
reduced in size, which is associated with a severe decrease in 
cellularity. Jak1 loss of function is also associated with pro-
found abnormalities in the B cell compartment caused by a 
block in diff  erentiation at the pro  –  B/pre  –  B cell transition 
step, resulting in a defi  cit in the production of mature B lym-
phocytes (  10  ). Based on its crucial role in lymphocyte pro-
liferation, survival, and diff  erentiation, we hypothesized that 
up-regulation of JAK1 signaling might contribute to malig-
nancies of the lymphoid lineage. In this study, we report that 
somatic activating   JAK1   mutations occur among adults with 
T cell precursors ALL, and are associated with poor response 
to therapy and overall prognosis. 
    RESULTS AND DISCUSSION   
    JAK1   mutation analysis in ALL 
  To explore possible contributions of somatic   JAK1   gene mu-
tations in ALL, genomic DNA samples from BM aspirates of 
adult subjects with B cell precursor ALL (B-ALL;   n   = 88) and 
T cell ALL (T-ALL;   n   = 38) obtained at diagnosis and before 
therapy were screened for mutations in the entire   JAK1   coding 
region using denaturing HPLC (DHPLC). Direct sequencing 
of variant elution profi  les allowed the identifi  cation of 37 in-
tronic and exonic changes, including 9 nonsynonymous vari-
ants observed in 14 individuals (  Table I   and Table S1, available 
at http://www.jem.org/cgi/content/full/jem.20072182/DC1).   
Among the missense defects, genotyping of genomic DNAs 
from BM obtained during remission demonstrated the somatic 
origin of the 1535C  >  T (Ser512Leu), 1901C  >  A (Ala634Asp), 
and 2171G  >  A (Arg724His) changes in the leukemic clones JEM VOL. 205, April 14, 2008  753
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Jak1 protein was observed in cultures maintained in the 
presence of IL-3 (  Fig. 2 D  ). Notably, we did not observe 
Jak1 phosphorylation in parental and transduced Ba/F3 cells 
basally and cultured in 2% WEHI-3B cell CM; however, 
phosphorylation was appreciable in A634D and R724H Jak1-
transduced cells after selection (7-d culture in absence of IL-3; 
unpublished data). 
  IL-9 protects the T cell lymphoma BW5147 cell line 
against dexamethasone-induced apoptosis (  12  ), an eff  ect that 
is dependent on Jak1-mediated Stat3 and Stat5 activation (  13  ). 
To demonstrate the activating role of the ALL-associated 
  JAK1   mutations in a diff  erent cellular system, BW5147 cells 
were transduced with WT   Jak1   or each of the selected 
  mutants to evaluate their eff  ect on this stress response. GFP-
expressing cells were isolated by fl  ow cytometry, cultured in 
the presence of cyclosporine A and dexamethasone, with or 
without IL-9, and [  3  H]thymidine incorporation was deter-
mined to assess proliferation (  Fig. 2 E  ). Three independent 
experiments documented that expression of the A634D and 
R879C Jak1 mutants, but not R724H Jak1, conferred in-
creased growth to cells basally. Of note, whereas transduced 
cells exhibited comparable responses to high levels of IL-9, 
those expressing the A634D and R879C Jak1 mutants were 
more responsive to low levels of the cytokine. Expression of 
the A634D Jak1, but not that of the R879C mutant, was as-
sociated with enhanced phosphorylation of Jak1, Stat3, and 
Stat5 basally (unpublished data). 
WT JAK1. Of note, basal STAT1 phosphorylation was ob-
served in cells expressing the A634D mutant, suggesting 
ligand-independent up-regulation of the kinase. Consistent 
with this, expression of the A634D mutant resulted in an 
essentially constitutive STAT1 transcriptional activation, 
whereas a statistically signifi  cant increase in STAT1 activity 
was observed in U4C cells expressing both the R724H and 
R879C mutants, basally and after stimulation (  Fig. 2 B  ). 
  To further assess the ability of mutations to up-regulate 
signal fl  ow, we transduced Ba/F3 cells with WT   Jak1   or each 
of the selected mutants to evaluate whether their expression 
induced autonomous growth of cytokine-dependent cells. 
GFP-expressing Ba/F3 cells were selected by fl  ow cytometry, 
cultured in 5 or 0.5% WEHI-3B cell conditional medium 
(CM) as a source of IL-3, as well as in absence of the cytokine, 
and counted to assess proliferation (  Fig. 2 C  ). Three indepen-
dent experiments indicated that expression of the A634D and, 
with less effi   ciency, R724H Jak1 mutants conferred IL-3  –
    independent growth to cells, whereas cells expressing WT Jak1 
or the R879C Jak1 mutant retained dependence on the cyto-
kine for survival. Of note, cells expressing each of the three 
mutants exhibited enhanced growth in response to IL-3. 
Consistent with these fi   ndings, Ba/F3 cells expressing the 
A634D Jak1 mutant exhibited enhanced Stat5, Akt, and ex-
tracellular signal-regulated kinase (ERK) phosphorylation ba-
sally and after stimulation, whereas a higher phosphorylation 
level of these signal transducers in cells expressing the R724H 
    Table I.        List of nonsynonymous   JAK1   changes identifi  ed in subjects with ALL 
Cohort and lineage Number of 
cases
Nucleotide 
substitution
Exon Amino acid 
substitution
Domain Mutation/ 
  polymorphism
Adult ALL
B-ALL 88
1 184A  >  G 2 Ile62Val FERM Polymorphism    a   
1  611A  >  T 5 Lys204Met FERM Mutation    b   
1 1901C  >  A 13 Ala634Asp Pseudokinase Mutation
1 2171G  >  A 15 Arg724His Pseudokinase Mutation    d   
T-ALL 38
1 184A  >  G 2 Ile62Val FERM Polymorphism    a   
1 1078C  >  T 7 Arg360Trp FERM Polymorphism    c   
1 1535C  >  T 10 Ser512Leu SH2 Mutation    d   
1 1901C  >  A 13 Ala634Asp Pseudokinase Mutation    d   
3 2171G  >  A 15 Arg724His Pseudokinase Mutation    e   
1 2635C  >  A 18 Arg879Ser Kinase Mutation    b,f   
1 2635C  >  T 18 Arg879Cys Kinase Mutation    b   
1 2636G  >  A 18 Arg879His Kinase Mutation    b   
Childhood ALL
B-ALL 85
T-ALL 49
1 1957C  >  T 13 Leu653Phe Pseudokinase Mutation    d   
  a  This change was observed in unaffected individuals.
  b  This change was not present among 335 population-matching control individuals.
  c  This change was present at remission.
  d  This change was not present at remission.
  e  This change was not present at remission in the one individual analyzed.
  f  This subject carried a concomitant 2171G  → A  change.754 SOMATIC   JAK1   MUTATIONS IN ALL | Flex et al.
kinase domain at the interface with the kinase domain in JAK2 
(Val  617  ) and JAK3 (Ala  572  ) promote increased catalytic activity 
basally (Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20072182/DC1) (  18  –  20  ). Our model also predicts 
that residues Lys  204   and Ser  512   would perturb the SH2  –  FERM 
interdomain interaction because they are located at the inter-
face between these domains, approximately facing each other. 
This fi  nding is noteworthy because it has been proposed that 
JAK1  ’  s SH2 domain does not function as a phosphotyrosyl-
binding domain, but instead plays a structural role in stabilizing 
the conformation of the FERM domain (  21  ), which mediates 
its association to cytokine receptors and exerts an as yet unchar-
acterized restraint on catalytic function (  22, 23  ). The molecular 
mechanism through which these mutations aff  ect JAK1 func-
tion remains to be explained. Structural and functional conse-
quences were not obvious for the activating changes aff  ecting 
residues Arg  724   and Arg  879  . 
  Gene expression profi  le analysis in blasts with a mutated 
  JAK1   allele 
  Total RNA was available from blasts of 5   JAK1   mutation-
positive (S512L, A634D, and R724H) and 11 mutation-
negative subjects of the T-ALL cohort. Unsupervised cluster-
ing based on 1,345 probe sets selected by nonspecifi  c fi  ltering 
clustered expression profi  les of mutation-positive blasts into 
two clusters, suggesting contribution of   JAK1   mutations to 
  Overall, these data indicated that the three selected leuke-
mia-associated   JAK1   mutants are hypermorphs, with A634D 
Jak1 having a seemingly stronger eff  ect, and that diff  erent 
mechanisms are likely to be involved in their cell context  –
  related gain of function. 
  Molecular modeling of JAK1 and location 
of affected residues 
  To look at the structural causes resulting in JAK1 functional 
up-regulation, we generated a model of JAK1 structure be-
cause no crystallographic information was available for this 
protein. Energy-minimized models of each of the four do-
mains were generated separately by homology to available 
crystallographic structures of proteins with similar sequences 
and overall fold. The quaternary arrangement of the four do-
mains was then determined by superimposing the models on a 
predicted three-dimensional structure of JAK2 (  14  ). Accord-
ing to the superimposed structure, Ala  634   and Leu  653   are placed 
on the surface of the pseudokinase domain involved in the in-
teraction with the kinase domain (  Fig. 1 B  ). Based on the evi-
dence supporting a negative regulatory role of the pseudokinase 
domain on catalytic function of JAK proteins (  15  –  17  ), the 
pathogenetic mechanism of the A634D and L653F changes is 
predicted to involve a looser interdomain interaction, relaxing 
inhibitory control on the kinase activity. Consistent with this 
hypothesis, substitution of two residues located in the pseudo-
    Figure 1.         Somatic   JAK1   mutations in ALL.   (A) Representative electropherograms showing the occurrence of somatically acquired   JAK1   mutations in 
subjects with T-ALL. In all cases, mutations were observed at diagnosis (top), but were undetectable during remission (bottom). (B) JAK1 domain structure 
and location of affected residues. The predicted amino acid substitutions resulting from the   JAK1   mutations are positioned below the diagram of the 
protein with its functional domains indicated (left) and shown in JAK1 three-dimensional modeled structure (right). (C) Electropherograms showing the 
occurrence of mutations in a fraction of leukemic cells of two individuals with T-ALL. In both patients, the mutant allele constituted only a portion of the 
amplifi  ed fragment from BM obtained at diagnosis (blasts   >  70% of total cells; top). The heterozygous status of each subject for an intragenic polymor-
phic site (bottom) is shown for comparison.     JEM VOL. 205, April 14, 2008  755
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known to be positively modulated by JAK/STAT signaling, 
including   IRF1  ,   SOCS3  ,   ISG15  ,   ISGF3G  ,   IFI44L  , and 
  IRF7  , were overrepresented in all the JAK1 mutation-positive 
subjects, further supporting the gain-of-function role of the 
ALL-associated   JAK1   lesions. 
  Clinical relevance of somatic   JAK1   mutations 
  The clinical relevance of   JAK1   mutations within the adult 
T-ALL cohort was investigated. Although no statistically 
distinct major mechanisms of deregulation (Fig. S2, available at 
http://www.jem.org/cgi/content/full/jem.20072182/DC1). 
Notably, supervised gene expression analysis revealed a dis-
tinctive expression signature shared by leukemic cells with a 
mutated   JAK1   gene (  Fig. 3 A  ) based on the expression of 
133 diff  erentially expressed probe sets, consisting of 112 dif-
ferentially expressed genes, the majority of them being over-
expressed in   JAK1   mutation-positive samples (Table S2).   
Among the up-regulated genes, those whose transcription was 
    Figure 2.         Functional effects of leukemia-associated   JAK1   mutations.   (A) STAT1 phosphorylation assays. Basal and IFN-    – stimulated  endogenous 
STAT1 phosphorylation in JAK1-defective U4C cells transiently transfected with WT   JAK1   or selected mutants. Blots are representative of three experi-
ments. (B) STAT1 activation assays. Basal and IFN-      –  stimulated endogenous STAT1 transcriptional activity in JAK1-defective U4C cells transiently cotrans-
fected with p-GAS-Luc and phRL-TK constructs, and WT   JAK1   or a mutant allele. STAT1-induced luciferase gene expression levels were determined by 
measuring the luciferase activity (CPS, counts per second) normalized to the activity of the Renilla luciferase, using a dual-luciferase reporter assay sys-
tem. Activity ratios are expressed as the mean of three replicates   ±   the SD. (C) Ba/F3 survival assays. WT or mutant   Jak1  -transduced Ba/F3 cells were 
grown in the absence of IL-3 (top) or with 0.5 or 5% WEHI-3B cell CM as source of IL-3 (bottom). Cell numbers (mean of three replicates   ±   the SD) were 
counted at the indicated time points (top) or at day 3 of culture (bottom). (D) Stat5, Akt, and ERK phosphorylation assays. Endogenous Stat5 Tyr694, Akt 
Ser473, and ERK1/2 Thr202/Tyr204 phosphorylation levels from lysates of Ba/F3 cells transduced with WT Jak1 or a mutant form and cultured without 
IL-3 (left) or with 2% WEHI-3B cell CM as the source of IL-3 (right). Activation of Stat5 (pStat5/Stat5), AKT (pAkt/Akt), and ERK1/2 (pERK/ERK) is expressed 
as a multiple of activation in untransduced cells. Blots are representative of at least three experiments performed. (E) BW5147 proliferation assays. WT or 
mutant   Jak1   transduced BW5147 cells were grown in presence of 200   μ  g/ml dexamethasone and 50   μ  g/ml cyclosporine A, in absence (left) or with differ-
ent concentrations (right) of IL-9. After 72 h, proliferation was measured after [  3  H]thymidine was added to the cultures (6 h). Data are shown as the 
means of three replicates   ±   the SD. For convenience, the amino acid changes affecting residues Ala  633 ,  Arg 723  , and Arg  878   of the murine Jak1 protein 
(encoded by the pMX-Jak1-IRES-GFP constructs used to transduce the Ba/F3 and BW5147 cell lines) are indicated according to the homologous residues 
in human JAK1.     756 SOMATIC   JAK1   MUTATIONS IN ALL | Flex et al.
signifi  cance of these associations (DFS: HR= 6.20, 95% CI = 
1.32  –  29.09, P = 0.02; OS: HR = 2.82, 95% CI = 1.07  –  7.48, 
P = 0.04), and excluded a signifi  cant contribution of patients  ’   
age (DFS: HR = 0.99, 95% CI = 0.93  –  1.05, P = 0.64; OS: 
HR= 1.01, 95% CI = 0.97  –  1.05, P = 0.60). 
  In the adult T-ALL cohort, the mutation status for  NRAS  , 
  KRAS  ,   NOTCH1  , and   PTEN   was also assessed (unpub-
lished data). Among the   JAK1   mutation-positive cases, no 
defect was observed in the   NRAS  ,   KRAS  , and   PTEN   genes, 
although such mutations had a relatively low prevalence in 
the entire adult T-ALL cohort (  RAS   genes: 11% of cases, 
95% CI = 2.9  –  24.8%;   PTEN  : 14% of cases, 95% CI = 4.5  –
  28.8%). In contrast, heterozygous mutations in   NOTCH1   
were observed in all   JAK1   mutation-positive individuals. 
Given the high prevalence of   NOTCH1   defects observed 
in the cohort (70% of cases, 95% CI = 53.0  –  84.1%), this 
association was not statistically signifi  cant (P = 0.06). This 
observation, however, suggests that activation of   JAK1   and 
  NOTCH1   transduction pathways might cooperate in T-ALL 
pathogenesis and/or progression. No signifi  cant diff  erence 
in response to therapy or outcome was observed between 
  NOTCH1   mutation-positive and -negative patients. Inter-
estingly,   NOTCH1   and   PTEN   mutations exhibited a mutu-
ally exclusive distribution because none of the fi  ve subjects 
carrying   PTEN   lesions had a   NOTCH1   defect (Fisher  ’  s exact 
probability = 0.001). 
  Aberrant   JAK1   function and leukemogenesis 
  Functional up-regulation of two members of the JAK fam-
ily, JAK2 and JAK3, has recently been discovered in myelo-
proliferative disorders and other malignancies of the myeloid 
lineage (  18  –  20, 24  ). The JAK2 V617F amino acid change 
occurs in the majority of polycythemia vera cases and in 
    50% of individuals with essential thrombocythemia or 
idiopathic myelofi  brosis. The available data support the 
view that this recurrent change, which aff  ects the pseudoki-
nase domain of the protein, induces constitutive activation 
of the kinase and hypersensitivity to cytokines. Similarly, 
three   JAK3   hypermorphic alleles promoting cytokine inde-
pendence in Ba/F3 cells have been identifi  ed in acute mega-
karyoblastic myeloid leukemia. In this study, we showed that 
somatically acquired activating   JAK1   mutations occur in 
ALL, particularly in adults, further emphasizing the impor-
tance of JAK-mediated signaling dysregulation in leukemo-
genesis and extending the spectrum of hematologic malignancies 
associated with aberrant activation of this signal transduc-
tion pathway. Even though the molecular mechanisms by 
which individual   JAK1   mutations promote gain of function 
are likely to be diverse and remain to be fully characterized, 
modeling and biochemical data are consistent with the view 
that, similar to what has been observed for somatic leuke-
mia-associated   JAK2   and   JAK3   defects, most mutations 
would interfere with the autoinhibitory control on the cat-
alytic activity. For most mutations, this eff  ect would be 
achieved by triggering local structural rearrangements in re-
gions involved in interdomain interactions between the 
signifi  cant diff  erence was observed in white blood cell counts, 
gender distribution, or association with specifi  c chromosomal 
rearrangements, patients with a mutated   JAK1   allele tended 
to have a more advanced age at diagnosis (median = 40.6 vs. 
24.2; P   <   0.01), which was consistent with the lower preva-
lence of mutations identifi  ed among children and adolescents 
with T-ALL included in the study. Comparison of the 
response to therapy between   JAK1   mutation-positive and 
-negative patients indicated a higher percentage of cases 
exhibiting resistance to induction therapy in the former 
(43 vs. 20%), although this diff  erence did not reach statistical 
signifi  cance caused by the relatively small size of the study 
cohort. Consistent with that fi  nding, a statistically signifi  cant 
reduced disease-free survival (DFS; median =8.7 vs. 20.5 mo; 
P = 0.01) and overall survival (OS; median = 10.6 vs. 32.5; 
P   <   0.01) was observed among   JAK1   mutation-positive pa-
tients (  Fig. 3 B  ). Multivariate analysis confi  rmed the statistical 
    Figure 3.         Gene expression profi  les and clinical relevance of 
somatic   JAK1   mutations in adult T-ALL.   (A) Supervised hierarchical 
clustering of gene expression profi  les performed on blasts from 16 adult 
T-ALL patients, with (orange) or without (green) a   JAK1   mutation. 
(B) Kaplan-Meier estimates of DFS (top) and OS (bottom) in subjects with 
(red) or without (black) a   JAK   mutation. Multivariate analysis confi  rmed 
the statistical signifi  cance of the reduced DFS and OV among   JAK1   mutation-
positive patients, and excluded a signifi  cant contribution of the more 
advanced age of these subjects.     JEM VOL. 205, April 14, 2008  757
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tagged   JAK1   cDNA cloned in pRc/CMV vector provided by S. Pellegrini 
(Pasteur Institute, Paris, France). JAK1-defective human fi  brosarcoma U4C 
cells (provided by S. Pellegrini) were maintained in DME supplemented 
with 10% heat-inactivated FCS and antibiotics. To evaluate endogenous 
STAT1 phosphorylation, after starvation (24 h), transiently transfected cells 
were stimulated with IFN-     (1,000 U/ml, 15 min) or left unstimulated. 
Lysed samples were analyzed by 10% SDS-PAGE, transferred to a polyvi-
nylidene difl  uoride membrane (Pierce Chemical Co.) and probed with anti  –
  phospho-Stat1 (9171; Cell Signaling Technology), anti-Stat1 (9172; Cell 
Signaling Technology), and anti-Jak1 (3332; Cell Signaling Technology) 
antibodies. Endogenous STAT1 transcriptional activity was assessed by lucif-
erase transactivation assays in cells cotransfected with a p-GAS-Luc con-
struct, switched to serum-starvation medium (8 h), and then stimulated with 
IFN-     (1,000 U/ml, 16 h) or left unstimulated. STAT1-induced luciferase 
expression was assessed and normalized using a dual luciferase reporter assay 
system (Promega) and a phRL-TK plasmid constitutively expressing the Re-
nilla luciferase. 
  Each of the three leukemia-associated mutations was also introduced 
in the murine Jak1 cDNA cloned in the bicistronic retroviral vector pMX-
IRES-GFP. Constructs were transfected into Phoenix or BOSC packag-
ing cells to produce retroviruses, and murine Ba/F3 (maintained in RPMI 
1640 medium containing 10% FCS, 1% l-glutamine, and 10% WEHI-3B 
cell CM) and BW5147 (maintained in Iscove-Dulbecco’s medium supple-
mented with 10% FBS, 0.55 mM l-arginine, 0.24 mM l-asparagine, and 
1.25 mM l-glutamine) cells were infected with retroviral supernatants. GFP-
positive populations were purifi  ed by fl  ow-cytometric sorting, and then ex-
panded. Equal GFP expression levels of transduced cells were confi  rmed by 
FACS analysis (Fig. S3, available at http://www.jem.org/cgi/content/full/
jem.20072182/DC1). Transduced Ba/F3 cells were cultured in the absence 
or presence of IL-3 (0.5 or 5% WEHI-3B cell CM) for assaying cytokine 
independence and response, and viable cells were counted by Trypan blue 
exclusion. Proliferation of transduced BW5147 cells cultured in the presence 
of 50 μg/ml cyclosporine A and 200 μg/ml dexamethasone, in the presence 
or absence of mIL-9, was determined using [3H]thymidine incorporation 
assay. In brief, 3,000 cells were seeded in 96-well plates (200 μl volume 
medium), and after 72 h, [3H]thymidine was added to the cultures for 6 h. 
Cells were then collected on microfi  lter plates, and thymidine incorporation 
was measured after addition of 25 μl of liquid scintillant. For Western blot 
studies, Ba/F3 cells were starved in RPMI 1640 medium containing 1% 
BSA (5 h), and then stimulated with 2% WEHI-3B cell CM (30 min) or 
left unstimulated, whereas BW5417 cells were starved in Iscove-Dulbecco’s 
medium (12 h) and left unstimulated or stimulated with 100 U/ml mIL-9 for 
15 min. Evaluation of Jak1, Akt, Stat3, Stat5, and ERK1/2 expression and 
phosphorylation levels was performed using anti–phospho-Jak1, anti-Jak1, 
anti–phospho-Akt, anti-Akt, anti–phospho-Stat3, anti-Stat3, anti–phospho-
Stat5, anti-Stat5, anti–phospho-p44/42 ERK, and anti-p44/42 ERK anti-
bodies (all from Cell Signaling Technology). 
  Structural models of the kinase, pseudokinase, and SH2 and FERM do-
mains of JAK1 were generated as described in the online supplemental infor-
mation section. 
  Statistical analysis.     Confidence intervals of proportions (at 95% level) 
were calculated based on the binomial distribution. The probabilities of 
OS and DFS were estimated using the Kaplan-Meier method. The log-
rank test was used to compare treatment effect and risk factor cate-
gories. All tests were two-sided, accepting P   ≤   0.05 as indicating a 
statistically significant difference. Cox proportional hazard models, in-
cluding age and   JAK1   as variables, were used to perform multivariate 
analyses for OS and DFS. The SAS software (SAS Institute) was used 
for the analysis. 
  Online supplemental material.     Methodologies and approaches used to 
generate the JAK1 molecular modeling and to perform and analyze adult 
T-ALL leukemic cell gene expression profi  les (including cited references) are 
provided in the Supplemental Materials and methods. Table S1 is a list of the 
pseudokinase and kinase domains or the FERM and SH2 
domains (Fig. S1). 
  JAK1 is expressed widely and participates in intracellular 
signaling elicited by class II cytokine receptors and receptors 
that use the gp130 or       c   receptor subunit. Although the he-
matopoietic defects in   Jak1        /      mice were restricted to the 
lymphoid cell compartment as a result of an impaired re-
sponse to IL-7 (  10  ) and the present fi  ndings indicate a cell-
context dependence of somatically acquired   JAK1   mutations  ’   
contribution to leukemogenesis, we cannot exclude the in-
volvement of this kinase in other malignancies. We speculate 
that a concomitant genetic event, including a mutation af-
fecting other members of the JAK family, might synergize 
with the   JAK1   defect to promote aberrant cell proliferation 
and/or survival in a cell-specifi  c context. This hypothesis is 
currently under investigation. 
  Although 70  –  80% of pediatric patients with either B- or 
T-ALL have excellent long-term response to intensive 
combination chemotherapy, adult patients exhibit a less fa-
vorable outcome (  4, 25  ). In B- ALL, such a poor prognosis 
has been associated in part with the presence of   BCR  /  ABL   
or   ALL1  /  AF4   gene rearrangements. In contrast, the unfa-
vorable outcome of adult patients with T-ALL has not con-
clusively been attributed to any cytogenetic lesion, albeit 
the prognostic relevance of aberrant   ERG   and   TLX1   gene 
expression and   NOTCH1   mutations has recently been re-
ported (  26  –  28  ). The present work provides the fi  rst evidence 
that   JAK1   gene defects are associated with a poor response 
to therapy, frequent relapse of the disease, and reduced OS, 
identifying such mutations as a novel informative prognos-
tic marker occurring in a sizable proportion of adult T-ALL. 
Although studies on larger cohorts are required to deter-
mine more precisely the clinical relevance and prognostic 
value of   JAK1   defects in adult and pediatric ALL, our fi  nd-
ings provide a rationale for the development of novel thera-
peutic approaches tailored at interfering with JAK1 signaling, 
encouraging studies aimed at testing the effi   cacy and side 
eff   ects of JAK1 inhibitors in the management of adult 
T-ALL patients  .   
    MATERIALS AND METHODS   
  All cohorts and molecular analyses.     Cohorts studied included patients 
enrolled in the Gruppo Italiano Malattie Ematologiche dell  ’  Adulto 0496 and 
2000 (adults), and Associazione italiana ematologia ed oncologia pediatrica 
ALL 2000 (children and adolescents) clinical trials. Written informed con-
sent for genetic analyses was obtained from all subjects according to the 
Declaration of Helsinki. BM mononuclear cells were isolated by density 
gradient centrifugation, and then cryopreserved. Genomic DNA was iso-
lated in a standard fashion. Exons 26, 27, and 34 of the   NOTCH1   gene were 
analyzed by direct sequencing, whereas the entire   JAK1   and   PTEN   coding 
regions and exons 1 and 2 of   NRAS   and   KRAS   were screened by DHPLC 
(Wave 2100 System; Transgenomic) and sequencing. Primer sequences are 
available upon request. Gene expression profi  ling methodology is described 
in the Supplemental materials and methods (available at http://www.jem
.org/cgi/content/full/jem.20072182/DC1). 
  Functional studies.     The mutations resulting in the A634D, R724H, and 
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intronic or synonymous   JAK1   changes identifi  ed in the study. Table S2 is a 
list of diff  erentially expressed genes in   JAK1   mutation-positive versus muta-
tion-negative adult subjects with T-ALL. Fig. S1 shows the JAK1 domain 
structure and the location of JAK1, JAK2, and JAK3 residues reported to be 
mutated in myeloproliferative disorders and leukemias. Fig. S2 shows the 
unsupervised hierarchical clustering of gene expression profi  les of blasts from 
16 adult T-ALL patients, with or without a   JAK1   mutation. Fig. S3 shows 
the GFP expression levels of purifi  ed Ba/F3 and BW5417 cells transduced 
with a bicistronic retroviral vector pMX-Jak1-IRES-GFP coding for WT 
Jak1 or one of the three generated mutants. The online version of this article 
is available at http://www.jem.org/cgi/content/full/jem.20072182/DC1. 
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